GoodRx Holdings shares are trading higher possibly after Eli Lilly said Zepbound 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription. GoodRx offers savings for tirzepatide, the generic form of Mounjaro and Zepbound.
Portfolio Pulse from Benzinga Newsdesk
GoodRx Holdings shares are rising following Eli Lilly's announcement that Zepbound vials are available for self-pay. GoodRx provides savings for tirzepatide, the generic form of Zepbound.
August 27, 2024 | 2:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GoodRx Holdings shares are trading higher after Eli Lilly announced the availability of Zepbound vials for self-pay. GoodRx offers savings on tirzepatide, the generic form of Zepbound, which may increase its usage and benefit GoodRx.
The availability of Zepbound vials for self-pay could lead to increased demand for tirzepatide, which GoodRx offers savings on. This could result in higher usage of GoodRx's services, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80